Navigation Links
China Medical Technologies Reports Second Fiscal Quarter Financial Results
Date:11/17/2010

BEIJING, Nov. 17, 2010 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based advanced in-vitro diagnostic ("IVD") company, today announced its unaudited financial results for the second fiscal quarter ended September 30, 2010 ("2Q FY2010").

2Q FY2010 Highlights

  • Revenues increased by 21.5% year-over-year to RMB201.8 million (US$30.2 million).
  • Non-GAAP net income, as defined below, increased 270.1% year-over-year to RMB65.4 million (US$9.8 million).
  • Non-GAAP diluted earnings per ADS*, as defined below, increased 273.1% year-over-year to RMB2.50 (US$0.37).
  • Adjusted EBITDA, as defined below, increased 62.6% year-over-year to RMB116.3 million (US$17.4 million).
  • Net cash generated from operations was RMB67.3 million (US$10.1 million).

  • Outlook for 3Q FY2010

  • Target revenues are expected to be not less than RMB220.0 million (US$32.9 million), representing a year-over-year increase of not less than 27.7%.
  • Target non-GAAP net income is expected to be not less than RMB74.0 million (US$11.1 million), representing a year-over-year increase of not less than 62.2%.
  • Target non-GAAP diluted earnings per ADS* is expected to be not less than RMB2.82 (US$0.42), representing a year-over-year increase of not less than 62.1%.

  • Outlook for FY2010

  • Target revenues are expected to be not less than RMB846.0 million (US$126.4 million), representing a year-over-year increase of not less than 17.0%. The year-over-year increase of annual revenues for FY2010 is lower than that of 3Q FY2010 because of the 10.9% year-over-year decrease in quarterly revenues of 1Q FY2010.
  • Target non-GAAP net income is expected to be not less than RMB280.0 million (US$41.9 million), representing a year-over-year increase of not less than 49.5%.
  • Target non-GAAP diluted earnings per ADS* is expected to be not less than RMB10.69 (US$1.60), representing a year-over-year increase of not less than 49.9%.

  • The above targets are based on the Company's current views on the operating and market conditions, which are subject to change.

    *One American Depositary Share ("ADS") = 10 ordinary shares

    See "Non-GAAP Measure Disclosures" below, where the impact of certain items on reported results is discussed.

    "We are pleased to see the commencement of contribution from sales of HPV-DNA chips which are expected to become another main revenue stream and an important growth driver in addition to our FISH business during the next few years. We have received strong interest in our SPR equipment from many of our top tier hospital customers and significant purchase orders on our chips from hospitals which have used our chips for their patients on a regular basis. We expect substantial growth on sales of our chips in upcoming quarters. In addition, our FISH business continued its growth momentum and our ECLIA business has resumed year-over-year growth," commented Mr. Xiaodong Wu, Chairman and Chief Executive Officer of the Company.

    2Q FY2010 Unaudited Financial ResultsThe Company reported revenues of RMB201.8 million (US$30.2 million) for 2Q FY2010, representing a 21.5% increase from the corresponding period of FY2009.

    The Company's revenues are currently generated from two segments, molecular diagnostic systems and immunodiagnostic systems. The molecular diagnostic system segment includes FISH products and SPR products while the immunodiagnostic system segment consists of ECLIA products.  

    Molecular diagnostic system sales for 2Q FY2010 were RMB118.3 million (US$17.7 million), representing a 32.6% increase from the corresponding period of FY2009. The year-over-year increase was primarily due to the increase in usage of the Company's FISH probes by existing and new hospital customers served by the Company's direct sales personnel as well as the sales of SPR-based HPV-DNA chips of RMB3.8 million (US$0.6 million) to hospitals during 2Q FY2010.

    Immunodiagnostic system sales for 2Q FY2010 were RMB83.5 million (US$12.5 million), representing an 8.7% increase from the corresponding period of FY2009. The year-over-year increase was primarily due to the increase in sales of the Company's ECLIA reagent kits to existing and new distributors.

    Gross margin was 55.2% for 2Q FY2010 which decreased year-over-year from 65.4% for the corresponding period of FY2009. Due to the commencement of sales of HPV-DNA chips, the amortization of SPR intangible assets amounted to RMB27.3 million (US$4.1 million) was classified from operating expenses to cost of revenues starting from 2Q FY2010. The year-over-year decrease in gross margin was primarily due to this change in classification. The gross margin for 2Q FY2010 would be 68.6% without this change in classification of expense.

    Research and development expenses were RMB10.9 million (US$1.6 million) for 2Q FY2010, representing a 14.5% year-over-year increase. The year-over-year increase was primarily due to product research and development for FISH probes and SPR chips.

    Sales and marketing expenses were RMB21.5 million (US$3.2 million) for 2Q FY2010, representing a 23.2% year-over-year increase. The year-over-year increase was primarily due to the increase in direct sales efforts for molecular diagnostic systems.

    General and administrative expenses were RMB25.0 million (US$3.7 million) for 2Q FY2010, representing a 44.5% year-over-year decrease. The year-over-year decrease was primarily due to no cost of independent internal investigation and lower allowance for doubtful accounts for 2Q FY2010.

    Interest expense on convertible notes was RMB32.0 million (US$4.8 million) for 2Q FY2010. As of September 30, 2010, the Company's outstanding convertible notes of US$135 million and US$248 million bear interest at 3.5% and 4% per annum, respectively, and will mature in November 2011 and August 2013, respectively.

    Interest expense on amortization of convertible notes issuance costs was RMB3.9 million (US$0.6 million) for 2Q FY2010.

    Interest expense on amortization of share lending costs was RMB2.5 million (US$0.4 million) for 2Q FY2010.

    Income tax expense was RMB21.8 million (US$3.3 million) for 2Q FY2010. The significant income tax expense was primarily because certain expenses of the Company such as stock compensation expense, amortization of acquired intangible assets and interest expense of convertible notes were not deductible for income tax purpose. In addition, the Company was required to accrue for withholding income tax on distributable earnings generated in China during 2Q FY2010.

    Net loss was RMB2.9 million (US$0.4 million) for 2Q FY2010, representing a 94.1% decrease from the corresponding period of FY2009. The significant year-over-year decrease in net loss was primarily due to growth in molecular diagnostic system sales and recovery from immunodiagnostic system sales.

    Non-GAAP net income, as defined below, was RMB65.4 million (US$9.8 million) for 2Q FY2010, representing a 270.1% increase from the corresponding period of FY2009.

    Earnings before interest, taxes, depreciation and amortization ("EBITDA") was RMB107.1 million (US$16.0 million) for 2Q FY2010, representing a 66.8% increase from the corresponding period of FY2009.

    Adjusted EBITDA, which excludes stock compensation expense and gain on purchase of convertible notes from EBITDA, was RMB116.3 million (US$17.4 million) for 2Q FY2010, representing a 62.6% increase from the corresponding period of FY2009.

    Stock compensation expense for 2Q FY2010 was RMB9.2 million (US$1.4 million), of which RMB0.1 million was allocated to cost of revenues, RMB1.1 million to research and development expenses, RMB0.2 million to sales and marketing expenses and RMB7.8 million to general and administrative expenses. The Company approved the grant of 2,100,000 restricted stock, equivalent to 210,000 ADSs, to directors, officers and certain employees on November 5, 2010. The restricted stock vests at the end of a three-year period.

    Amortization of acquired intangible assets for 2Q FY2010 was RMB49.4 million (US$7.4 million) which was all allocated to cost of revenues.

    As of September 30, 2010, the Company's cash and cash equivalents was RMB805.9 million (US$120.5 million). Net cash generated from operating activities for 2Q FY2010 was RMB67.3 million (US$10.1 million). Net cash used in investing activities for 2Q FY2010 was RMB1.2 million (US$0.2 million). There was no financing activity for 2Q FY2010.

    As of September 30, 2010, the Company's net accounts receivable was RMB333.1 million (US$49.8 million), representing an increase of 7.0% from the balance at June 30, 2010.

    For the convenience of readers, certain RMB amounts have been translated into U.S. dollars at the rate of RMB6.6905 to US$1.00, the noon buying rate in New York City for cable transfers of RMB per U.S. dollar as set forth in the H.10 weekly statistical release of the Federal Reserve Board, as of Thursday, September 30, 2010. No representation is made that the RMB amounts could have been or could be converted into U.S. dollars at that rate or at any other rate on September 30, 2010 or at any other dates.

    Update on Receivable from ChengxuanThe receivable of US$30 million from Chengxuan, one of the Company's major shareholders and owned by Mr. Xiaodong Wu, is due on December 31, 2010 which relates to the sale of the Company's HIFU business to Chengxuan. Chengxuan made an early payment of US$8 million to the Company in November 2010 and has indicated to the Company that the remaining amount will be paid on or before December 31, 2010.

    Non-GAAP Measure DisclosuresThe Company provides gross profit, operating income, net income, earnings per ADS, EBITDA and adjusted EBITDA on a Non-GAAP basis to enable investors to better assess the Company's operating performance. The Non-GAAP measures described by the Company are reconciled to the corresponding GAAP measures in the exhibit below titled "Reconciliations of GAAP measures to Non-GAAP measures".

    The Company reported for 2Q FY2010 and provided estimates of net income and diluted earnings per ADS for 3Q FY2010 and full year FY2010 on a Non-GAAP basis. Each of the terms used by the Company is defined as follows:

  • Non-GAAP gross profit represents gross profit reported in accordance with GAAP, adjusted for the effects of stock compensation expense and amortization of acquired intangible assets.
  • Non-GAAP operating income represents operating income reported in accordance with GAAP, adjusted for the effects of stock compensation expense and amortization of acquired intangible assets.
  • Non-GAAP net incomerepresents net income reported in accordance with GAAP, adjusted for the effects of stock compensation expense, amortization of acquired intangible assets, non-cash interest expense of convertible notes, non-cash interest expense for amortization of share lending costs and gain on purchase of convertible notes.
  • Non-GAAP earnings per ADS represents Non-GAAP net income divided by the weighted average number of ADSs used in computing basic and diluted earnings per ADS in accordance with GAAP.
  • EBITDA represents net income reported in accordance with GAAP, adjusted for the effects of interest income, interest expenses, income tax expense, depreciation as well as amortization of acquired intangible assets.
  • Adjusted EBITDA represents EBITDA adjusted for the effects of stock compensation expense and gain on purchase of convertible notes.

  • Non-GAAP financial measures are used by the Company in its financial and operating decision-making because management believes they reflect the Company's ongoing business in a manner that allows meaningful period-to-period comparison. The Company's management believes that these non-GAAP financial measures provide useful information to investors and others in understanding and evaluating the Company's current operating performance and future prospects in the same manner as management does, if they so choose.

    The presentation of this additional financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. For a reconciliation of the non-GAAP financial measures to the most directly comparable GAAP financial measures, please see the financial information included with this earnings announcement.

    Conference CallThe Company's senior management team will host an earnings conference call at 8:00 a.m. U.S. Eastern Time on November 17, 2010 (or 9:00 p.m. Beijing/Hong Kong time on the same date) to discuss the results following this earnings announcement.

    The dial-in details for the live conference call are as follows:U.S. Toll Free Number 1-800-591-6923International Dial-in Number 1-617-614-4907Passcode: CMEDCALLA live webcast of the conference call will be available on http://ir.chinameditech.com.

    A replay of this webcast will be available for one month on this website.

    A telephone replay of the call will be available after the conclusion of the conference call through 10:00 a.m. U.S. Eastern Time on November 18, 2010.  

    The dial-in details for the replay are as follows:U.S. Toll Free Number 1-888-286-8010International Dial-in Number 1-617-801-6888Passcode: 10798661About China Medical Technologies, Inc.China Medical Technologies, Inc. is a leading China-based advanced IVD company using molecular diagnostic technologies including Fluorescent in situ Hybridization (FISH) and Surface Plasmon Resonance (SPR) and an immunodiagnostic technology, Enhanced Chemiluminescence Immunoassay (ECLIA), to develop, manufacture and distribute diagnostic products used for the detection of various cancers, diseases and disorders as well as companion diagnostic tests for targeted cancer drugs. The Company generates all of its revenues in China through the sale of diagnostic consumables including FISH probes, SPR-based DNA chips and ECLIA reagent kits to hospitals which are recurring users of the consumables for their patients. The Company sells FISH probes and SPR chips to large hospitals through its direct sales force and ECLIA reagent kits to small and mid-size hospitals through distributors. For more information, please visit http://www.chinameditech.com.

    Safe Harbor StatementThis press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the quotations from management in this press release, as well as its outlook for 3Q FY2010 and full year FY2010, contain forward-looking statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Further information regarding these and other risks is included in the Company's filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

    ContactsSam Tsang and Winnie YamTel: +852-2511-9808Email: IR@chinameditech.comChina Medical Technologies, Inc.Unaudited Condensed Consolidated Balance SheetsAs  ofMarch 31,
    2010June 30,
    2010September 30,
    2010RMBRMBRMBUS$(in thousands)AssetsCurrent assetsCash and cash equivalents

    815,453

    742,340

    805,901

    120,455Trade accounts receivable, net

    303,368

    311,282

    333,123

    49,791Inventories

    24,889

    20,177

    21,351

    3,191Prepayments and other receivables

    21,508

    12,048

    19,093

    2,854Due from a related party

    204,774

    203,445

    200,715

    30,000  Total current assets

    1,369,992

    1,289,292

    1,380,183

    206,291Property, plant and equipment, net

    155,825

    151,621

    147,355

    22,024Land use rights

    7,049

    7,001

    6,954

    1,039Goodwill

    8,654

    8,654

    8,654

    1,293Intangible assets, net

    3,285,190

    3,216,535

    3,128,820

    467,651Convertible notes issuance costs

    46,681

    39,166

    34,782

    5,199Share lending costs

    35,678

    30,744

    27,905

    4,171Total assets

    4,909,069

    4,743,013

    4,734,653

    707,668Liabilities Current liabilitiesTrade accounts payable

    20,126

    24,136

    43,958

    6,570Accrued liabilities and other payables

    183,498

    186,036

    173,693

    25,960Income taxes payable

    57,529

    56,518

    59,334

    8,869Total current liabilities

    261,153

    266,690

    276,985

    41,399Convertible notes

    2,777,086

    2,556,014

    2,528,848

    377,976Deferred income taxes

    67,134

    72,518

    78,408

    11,720Total liabilities

    3,105,373

    2,895,222

    2,884,241

    431,095Shareholders' equityOrdinary shares US$0.1 par value:

    500,000,000 authorized; 322,680,001 issued and outstanding as of March 31, 2010, June 30, 2010 and September 30, 2010

    258,840

    258,840

    258,840

    38,688Additional paid-in capital

    808,221

    820,778

    830,016

    124,058Treasury stock

    (45,143)

    (47,108)

    (47,108)

    (7,041)Accumulated other comprehensive loss

    (70,556)

    (70,731)

    (74,412)

    (11,122)Retained earnings

    852,334

    886,012

    883,076

    131,990Total shareholders' equity

    1,803,696

    1,847,791

    1,850,412

    276,573Total liabilities and shareholders' equity

    4,909,069

    4,743,013

    4,734,653

    707,668China Medical Technologies, Inc.Unaudited Condensed Consolidated Statements of IncomeFor the Three Months EndedSeptember 30, 2009June 30, 2010September 30, 2010RMBRMBRMBUS$   As adjusted (4)(in thousands except for per ADS information)Revenues, net (1)

    166,066

    186,170

    201,834

    30,167Cost of revenues (2)

    (57,517)

    (61,354)

    (90,477)

    (13,523)Gross profit

    108,549

    124,816

    111,357

    16,644Operating expensesResearch and development (2)

    (9,500)

    (10,632)

    (10,877)

    (1,625)Sales and marketing (2)

    (17,432)

    (18,266)

    (21,473)

    (3,209)General and administrative (2)

    (45,130)

    (25,149)

    (25,048)

    (3,744) Amortization of SPR intangible assets

    (27,357)

    (27,329)

    -

    -Total operating expenses

    (99,419)

    (81,376)

    (57,398)

    (8,578)Operating income

    9,130

    43,440

    53,959

    8,066Interest income

    2,196

    4,597

    5,119

    765Interest expense – convertible notes

    (35,439)

    (32,505)

    (32,019)

    (4,786)Interest expense – amortization of convertible notes issuance costs

    (4,381)

    (4,012)

    (3,906)

    (584)Interest expense – amortization of share lending costs

    (2,756)

    (2,475)

    (2,456)

    (367) Other (expense) income, net

    (255)

    43,295

    (1,802)

    (269)Income (loss) before income tax

    (31,505)

    52,340

    18,895

    2,825Income tax expense

    (18,343)

    (18,662)

    (21,831)

    (3,263)Net income (loss)

    (49,848)

    33,678

    (2,936)

    (438)Earnings (loss) per ADS- basic

    (1.89)

    1.30

    (0.11)

    (0.02)- diluted (3)

    (1.89)

    1.29

    (0.11)

    (0.02)Weighted average number of ADS- basic

    26,432,974

    26,005,975

    26,117,308

    26,117,308- diluted (3)

    26,432,974

    26,128,403

    26,117,308

    26,117,308Notes:(1)  Revenues, net

    RMB'000RMB'000RMB'000US$'000- Molecular diagnostic systems

    89,233

    108,092

    118,347

    17,689- Immunodiagnostic systems

    76,833

    78,078

    83,487

    12,478166,066

    186,170

    201,834

    30,167Molecular diagnostic systems

    - HPV-DNA chips

    -

    18

    3,802

    568(2) Stock compensation expense

    RMB'000RMB'000RMB'000US$'000- Cost of revenues

    -

    52

    117

    18- Research and development

    1,256

    1,418

    1,145

    171- Sales and marketing

    -

    91

    204

    30- General and administrative

    6,098

    9,031

    7,772

    1,1627,354

    10,592

    9,238

    1,381(3) Interest expense and amortization in connection with convertible notes were not added back in computing diluted earnings per ADS because they were anti-dilutive.(4) As a result of the adoption of new authoritative guidance governing the accounting for own-share lending arrangements in contemplation of convertible debt issuance or other financing effective on April 1, 2010, the Company adjusted relevant numbers in the unaudited condensed consolidated statements of income for the three months ended September 30, 2009 retrospectively in accordance with GAAP.China Medical Technologies, Inc.Unaudited Condensed Consolidated Statements of Cash FlowsFor the Three Months EndedSeptember 30, 2009June 30, 2010September 30, 2010RMBRMBRMBUS$(in thousands)Net cash provided by operating activities

    45,472

    69,847

    67,303

    10,059Net cash used in investing activities

    (357,165)

    (1,289)

    (1,244)

    (186)Net cash provided by (used in) financing activities

    1,011

    (144,537)

    -

    -Effect of foreign currency exchange rate change on cash

    (155)

    2,866

    (2,498)

    (372)Net increase (decrease) in cash and cash equivalents

    (310,837)

    (73,113)

    63,561

    9,501Cash and cash equivalents:At beginning of period

    1,547,533

    815,453

    742,340

    110,954At end of period

    1,236,696

    742,340

    805,901

    120,455China Medical Technologies, Inc.Reconciliations of GAAP measures to Non-GAAmeasuresFor the Three Months EndedSeptember 30, 2009June 30, 2010September 30, 2010   RMBRMBRMBUS$As adjusted (2)(in thousands except for per ADS information)Gross profit

    108,549

    124,816

    111,357

    16,644Adjustments:Stock compensation expense

    -

    52

    117

    18   Amortization of acquired intangible assets

    22,430

    22,414

    49,422

    7,386Non-GAAP gross profit

    130,979

    147,282

    160,896

    24,048Gross margin

    65.4%

    67.0%

    55.2%

    55.2%Non-GAAP gross margin

    78.9%

    79.1%

    79.7%

    79.7%Operating income

    9,130

    43,440

    53,959

    8,066Adjustments:Stock compensation expense

    7,354

    10,592

    9,238

    1,381Amortization of acquired intangible assets

    49,787

    49,743

    49,422

    7,386Non-GAAP operating income

    66,271

    103,775

    112,619

    16,833Operating margin

    5.5%

    23.3%

    26.7%

    26.7%Non-GAAP operating margin

    39.9%

    55.7%

    55.8%

    55.8%Net income (loss)

    (49,848)

    33,678

    (2,936)

    (438)Adjustments:Stock compensation expense

    7,354

    10,592

    9,238

    1,381Amortization of acquired intangible assets

    49,787

    49,743

    49,422

    7,386Non-cash interest expense of convertible notes

    7,621

    7,916

    7,221

    1,079Non-cash interest expense – amortization of share lending costs

    2,756

    2,475

    2,456

    367Gain on purchase of convertible notes

    -

    (47,393)

    -

    -Non-GAAP net income

    17,670

    57,011

    65,401

    9,775GAAP net margin

    -

    18.1%

    -

    -Non-GAAP net margin

    10.6%

    30.6%

    32.4%

    32.4%Net income (loss)

    (49,848)

    33,678

    (2,936)

    (438)Adjustments:Interest income

    (2,196)

    (4,597)

    (5,119)

    (765)Interest expense – convertible notes

    35,439

    32,505

    32,019

    4,786Interest expense – amortization of convertible notes issuance costs

    4,381

    4,012

    3,906

    584Interest expense – amortization of share lending costs

    2,756

    2,475

    2,456

    367Income tax expense

    18,343

    18,662

    21,831

    3,263Depreciation

    5,521

    5,475

    5,497

    822Amortization of acquired intangible assets

    49,787

    49,743

    49,422

    7,386EBITDA

    64,183

    141,953

    107,076

    16,005EBITDA margin

    38.6%

    76.2%

    53.1%

    53.1%EBITDA

    64,183

    141,953

    107,076

    16,005Adjustments:Stock compensation expense

    7,354

    10,592

    9,238

    1,381Gain on purchase of convertible notes

    -

    (47,393)

    -

    -Adjusted EBITDA

    71,537

    105,152

    116,314

    17,386Adjusted EBITDA margin

    43.1%

    56.5%

    57.6%

    57.6%Earnings (loss) per ADS- basic

    (1.89)

    1.30

    (0.11)

    (0.02)- diluted

    (1.89)

    1.29

    (0.11)

    (0.02)Non-GAAP earnings per ADS- basic

    0.67

    2.19

    2.50

    0.37- diluted (1)

    0.67

    2.18

    2.50

    0.37Weighted average number of ADS- basic

    26,432,974

    26,005,975

    26,117,308

    26,117,308- diluted (1)

    26,432,974

    26,128,403

    26,117,308

    26,117,308Notes:(1) Interest expense and amortization in connection with convertible notes were not added back in computing non-GAAP diluted earnings per ADS because they were anti-dilutive.(2) As a result of the adoption of new authoritative guidance governing the accounting for own-share lending arrangements in contemplation of convertible debt issuance or other financing effective on April 1, 2010, the Company adjusted relevant numbers in the unaudited condensed consolidated statements of income for the three months ended September 30, 2009 retrospectively in accordance with GAAP.
    '/>"/>

    SOURCE China Medical Technologies, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved


    Related medicine technology :

    1. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
    2. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
    3. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
    4. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
    5. China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
    6. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
    7. Varian Medical Systems to Exhibit Cancer Treatment and X-ray Imaging Technologies at China Med Exhibition
    8. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
    9. China Animal Welfare Law Under Review While 36,000 Dogs Culled
    10. China-Biotics, Inc. Prices $69 Million Public Offering of Common Stock
    11. Clifford Chance Advises Pfizer on Conditional Clearance in China of Its Merger with Wyeth
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/24/2016)... 24, 2016 According to a ... (Standard Pen Needles, Safety Pen Needles), Needle Length (4mm, ... Hormone), Mode of Purchase (Retail, Non-Retail) - Trends & ... studies the market for the forecast period of 2016 ... 2.81 Billion by 2021 from USD 1.65 Billion in ...
    (Date:6/23/2016)... June 23, 2016  MedSource announced today that ... e-clinical software solution of choice.  This latest decision ... value to their clients by offering a state-of-the-art ... relationship establishes nowEDC as the EDC platform of ... full-service clients.  "nowEDC has long been a preferred ...
    (Date:6/23/2016)... 2016  In a startling report released today, National Safety ... lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... how states are tackling the worst drug crisis in recorded U.S. ... Kentucky , New Mexico , ... Of the 28 failing states, three – Michigan ...
    Breaking Medicine Technology:
    (Date:6/27/2016)... ... 27, 2016 , ... "FCPX editors can now reveal their media with growing ... said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color brings ... users can now reveal the media of their split screens with growing colorful panels. ...
    (Date:6/27/2016)... , ... June 27, 2016 , ... TopConsumerReviews.com recently awarded ... Eyeglasses . , Millions of individuals in the United States and Canada wear ... a way to both correct vision and make a fashion statement. Even celebrities use ...
    (Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
    (Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
    (Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
    Breaking Medicine News(10 mins):